← Eichor
Study identifier: NCT07027254 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism

Condition: Primary Aldosteronism · Secondary Hypertension · Aldosterone-Producing Adenoma  ·  Sponsor: Seoul National University Hospital

PhaseNA
Planned participants90
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET/CT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.

This description comes directly from the study's public registry record.

Talk to the study team

Seungho Lee, M.D  ·  82-10-8629-9209  ·  ganymedes10@gmail.com

Always discuss trial participation with your own doctor first.

Locations (2)

Samsung Medical CenterSeoul, Gangnam-gu, South KoreaRecruiting
Seoul National University HospitalSeoul, Jongno-gu, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07027254